PCIA
CORT icon

Prime Capital Investment Advisors’s Corcept Therapeutics CORT Stock Holding History

Prime Capital Investment Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$253K Buy
+2,915
New +$176K ﹤0.01% 933
2025
Q4 		– Sell
-2,944
Closed -$245K – 1045
2025
Q3 		$245K Sell
2,944
-4
-0.1% -$289 ﹤0.01% 871
2025
Q2 		$216K Sell
2,948
-16
-0.5% -$1.16K ﹤0.01% 876
2025
Q1 		$339K Buy
+2,964
New +$180K ﹤0.01% 797

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prime Capital Investment Advisors's CORT Position: Q2 2026 in Review

Prime Capital Investment Advisors opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 2,915 shares worth $253K. The stake represents ﹤0.01% of the portfolio and ranks #933 among its holdings. This is a return to the name: Prime Capital Investment Advisors previously reported a position in CORT as recently as Q3 2025.

Prime Capital Investment Advisors first reported a position in CORT in Q1 2025 and has held it in 4 quarters since. The position peaked at $339K in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Prime Capital Investment Advisors held 2,915 shares of Corcept Therapeutics worth $253K as of Q2 2026.
  • Corcept Therapeutics was a new Prime Capital Investment Advisors position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Prime Capital Investment Advisors's portfolio in Q2 2026, its #933 holding.
  • Prime Capital Investment Advisors first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Prime Capital Investment Advisors's Corcept Therapeutics position peaked at $339K in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.